Cargando…
Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder
Lisdexamfetamine dimesylate (LDX) is the first prodrug stimulant used for the treatment of attention-deficit/hyperactivity disorder (ADHD) dosed once daily. Due to its long-acting properties, LDX remains pharmacologically inactive until an enzymatic process predominantly associated with red blood ce...
Autores principales: | Najib, Jadwiga, Wimer, Dexter, Zeng, Julie, Lam, Kristina W, Romanyak, Natalya, Paige Morgan, Eva, Thadavila, Anu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5571766/ https://www.ncbi.nlm.nih.gov/pubmed/28855799 http://dx.doi.org/10.1177/1179573517728090 |
Ejemplares similares
-
Lisdexamfetamine Dimesylate for Preschool Children with Attention-Deficit/Hyperactivity Disorder
por: Childress, Ann C., et al.
Publicado: (2020) -
Effect of lisdexamfetamine dimesylate on sleep in adults with attention-deficit/hyperactivity disorder
por: Adler, Lenard A, et al.
Publicado: (2009) -
Lisdexamfetamine in the treatment of adolescents and children with attention-deficit/hyperactivity disorder
por: Najib, Jadwiga
Publicado: (2012) -
Efficacy and Safety of Lisdexamfetamine Dimesylate in Children with Attention-Deficit/Hyperactivity Disorder and Recent Methylphenidate Use
por: Jain, Rakesh, et al.
Publicado: (2013) -
Long‐term study of lisdexamfetamine dimesylate in Japanese children and adolescents with attention‐deficit/hyperactivity disorder
por: Ichikawa, Hironobu, et al.
Publicado: (2019)